Openbookopenbook
Equity
Aspire BioPharma, Inc.(ASBP)
USD --+0.00%
Reward43Moderate
Risk81High
📊50%Data
ASBP
+0.0 · +0.00%
USD · NASDAQ
Aspire BioPharma, Inc. | Healthcare
Capital Destroyer
Market Cap:1.23M
ℹ️
Reward Rating
43
Moderate
Bottom 25% (model universe)
50% data coverage
ℹ️
Risk Rating
81
High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on ASBP to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Aspire BioPharma, Inc.?

, an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States.

ASBP · Verdict

Moderate reward · high risk

ASBP has limited near-term tailwinds — balance sheet and cash flow weigh on the model output.

Based on 75% data coverage

ASBP · Verdict

What’s working & what to watch

Watchouts 3

  • Balance sheet6/100

    Current ratio 0.17

  • Cash flow7/100

    -79385% free-cash-flow margin

  • Profitability9/100

    -394725% net margin · 0% ROE

Model-based scoring. For information only — not financial advice.

What is Aspire BioPharma, Inc.?

, an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.23M.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Elevated volatility implies higher downside and expectation risk.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (43)

The scoring profile indicates limited reward potential at this time, with valuation and growth offering the most support. Risk indicators are high — this profile reflects meaningful downside exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap1.23M
P/E RatioN/A
Dividend YieldN/A
52 Week High35.012
52 Week Low0.1643
Last AnnualDecember
IPO Date4/11/2022
IncorporatedUSA
Shares Outstanding5M
No. of EmployeesN/A
IndustryBiotechnology
ExchangeNASDAQ
Beta0.996
CurrencyUSD
Websiteaspirebiolabs.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.